Cullinan Oncology
CGEM
106 hedge funds and large institutions have $397M invested in Cullinan Oncology in 2023 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 38 reducing their positions, and 20 closing their positions.
21% more capital invested
Capital invested by funds: $330M → $397M (+$67.8M)
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
11.67% more ownership
Funds ownership: 82.04% → 93.7% (+12%)
3% more funds holding
Funds holding: 103 → 106 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
21% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 38
89% less call options, than puts
Call options by funds: $43K | Put options by funds: $390K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$20.3M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$16.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$12.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.6M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$2.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.6M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.71M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.52M |
| 4 |
BlackRock
New York
|
-$1.61M |
| 5 |
AI
Atom Investors
Austin,
Texas
|
-$1.23M |
CGEM Hedge Fund Activity: Q2 2023 in Review
106 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q2 2023, worth a combined $397M — up 21% from $330M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CGEM positions and 20 closed out — a net gain of 3 holders — while 30 added to existing stakes and 38 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $20.3M. The largest seller was Vanguard Group, cutting an estimated $5.6M.
- 106 institutional investors held Cullinan Oncology (CGEM) as of Q2 2023, up from 103 in Q1 2023.
- Funds reported $397M of Cullinan Oncology stock for Q2 2023, up 21% quarter-over-quarter.
- 23 funds opened new Cullinan Oncology positions in Q2 2023 and 20 closed out, a net change of +3 holders.
- The largest Cullinan Oncology buyer in Q2 2023 was Braidwell, an estimated $20.3M added.
- The largest Cullinan Oncology seller in Q2 2023 was Vanguard Group, an estimated $5.6M sold.
Based on aggregated 13F filings for Q2 2023.